Immuneering’s (IMRX) Buy Rating Reaffirmed at Needham & Company LLC

Needham & Company LLC reaffirmed their buy rating on shares of Immuneering (NASDAQ:IMRX) in a research report report published on Monday,Benzinga reports. They currently have a $15.00 target price on the stock.

A number of other equities research analysts have also recently weighed in on IMRX. Chardan Capital reissued a “buy” rating and issued a $13.00 price target on shares of Immuneering in a research report on Wednesday, January 8th. Morgan Stanley cut Immuneering from an “equal weight” rating to an “underweight” rating in a research report on Friday, December 13th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $12.80.

Immuneering Stock Down 2.9 %

Shares of Immuneering stock opened at $2.01 on Monday. The firm has a market capitalization of $62.41 million, a P/E ratio of -1.02 and a beta of -0.34. Immuneering has a 52 week low of $1.00 and a 52 week high of $7.68. The firm’s 50 day moving average is $2.05 and its two-hundred day moving average is $1.78.

Institutional Investors Weigh In On Immuneering

Several hedge funds have recently made changes to their positions in IMRX. Corsair Capital Management L.P. purchased a new stake in Immuneering during the 3rd quarter valued at approximately $25,000. Vontobel Holding Ltd. acquired a new position in shares of Immuneering in the third quarter valued at approximately $25,000. XTX Topco Ltd raised its stake in shares of Immuneering by 37.3% during the second quarter. XTX Topco Ltd now owns 34,159 shares of the company’s stock worth $44,000 after purchasing an additional 9,274 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Immuneering during the second quarter worth $44,000. Finally, Tidemark LLC purchased a new position in Immuneering in the 3rd quarter valued at $129,000. Institutional investors and hedge funds own 67.65% of the company’s stock.

About Immuneering

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.